Tovetumab information

Tovetumab
Monoclonal antibody
Type	?
Source	Human
Target	PDGFRA
Clinical data
ATC code	none;
Identifiers
CAS Number	1243266-04-7;
ChemSpider	none;
UNII	2XY62K75UV;
KEGG	D10411;
Chemical and physical data
Formula	C6400H9906N1726O2002S54
Molar mass	144792.97 g·mol−1

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.^[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer.^[2] Development was discontinued in 2013.^[3]^[4]

This drug was developed by MedImmune, LLC.^{[citation needed]}

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L (November 2020). "A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy". The AAPS Journal. 23 (1): 4. doi:10.1208/s12248-020-00523-3. PMID 33210183. S2CID 227067803.
^ "Tovetumab". AdisInsight. Springer Nature Switzerland AG.
^ Williams R (January 2015). "Discontinued in 2013: oncology drugs". Expert Opinion on Investigational Drugs. 24 (1): 95–110. doi:10.1517/13543784.2015.971154. PMID 25315907. S2CID 23390614.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.

[pmid33210183-2] Liang M, Wang B, Schneider A, Vainshtein I, Roskos L (November 2020). "A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy". The AAPS Journal. 23 (1): 4. doi:10.1208/s12248-020-00523-3. PMID 33210183. S2CID 227067803.

[3] "Tovetumab". AdisInsight. Springer Nature Switzerland AG.

[pmid25315907-4] Williams R (January 2015). "Discontinued in 2013: oncology drugs". Expert Opinion on Investigational Drugs. 24 (1): 95–110. doi:10.1517/13543784.2015.971154. PMID 25315907. S2CID 23390614.

Tovetumab information

and 24 Related for: Tovetumab information

Tovetumab

Dexamethasone

Testosterone

Insulin

Amitriptyline

Erythropoietin

Osimertinib

Fruquintinib

Dehydroepiandrosterone

Neurotrophin

Amivantamab

Trastuzumab deruxtecan

Epidermal growth factor

Faricimab

Repotrectinib

Filgrastim

HER2

Nintedanib

Cerebrolysin

Tyrosine kinase inhibitor

Nerve growth factor

Alectinib

Encorafenib

Neurotrophic factors